Clinical Trials Browser

trametinib × CNS × 90 days × Clear all

NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 1 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT03975829 2026-06-02

Pediatric Long-Term Follow-up and Rollover Study

Phase 4 Recruiting

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Histiocytosis, Langerhans-Cell, Neuroblastoma, Neurofibromatosis 1, Oligodendroglioma, Ganglioglioma, Neurocytoma, Neurofibroma, Plexiform

NCT03190915 2026-05-27

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Phase 2 Active not recruiting

10 enrolled 11 charts

CNSOther hematologic neoplasm

Neurofibromatosis 1, Leukemia, Myelomonocytic, Juvenile

NCT03919071 2026-05-27

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

Phase 2 Active not recruiting

Astrocytoma, Glioblastoma, Glioma

NCT03363217 2026-04-24

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

Phase 2 Active not recruiting

Brain Neoplasms, Glioma, Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03340506 2026-04-20

Dabrafenib and/or Trametinib Rollover Study

Phase 4 Recruiting

CNSDermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Glioma, Lung Neoplasms, Melanoma

NCT05849662 2026-04-15

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Phase 1/2 Recruiting

CNSOther hematologic neoplasm

Neurofibromatosis 1, Leukemia, Myelomonocytic, Juvenile

NCT02015117 2026-04-13

Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases

Phase 1 Active not recruiting

Brain Neoplasms

NCT04485559 2026-04-13

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

Phase 1 Suspended

Glioma